Balloon Angioplasty Aids Chronic Thromboembolic Pulmonary Hypertension
FRIDAY, April 28, 2023 -- Balloon pulmonary angioplasty (BPA) with refined techniques can be effective for treating patients with chronic thromboembolic pulmonary hypertension (CTEPH), according to a study published online April 12 in JACC:... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 28, 2023 Category: Pharmaceuticals Source Type: news
Balloon Pulmonary Angioplasty Becoming Safer Over Time
MONDAY, April 10, 2023 -- Balloon pulmonary angioplasty (BPA) is becoming safer over time, with a reduction seen in complications from 2013-2017 to 2018-2022, according to a review published online March 22 in JACC: Cardiovascular... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 10, 2023 Category: Pharmaceuticals Source Type: news
Medtronic Launches Newest Drug-Eluting Stent: The Onyx Frontier ™
The major improvement is that it employs a more deliverable system: an innovative dual-layer balloon, a lower profile for crossing, and increased catheter flexibility. These refinements point to a 16% improvement in deliverability vs. the previous generation while maintaining superior radial strength. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 25, 2022 Category: Cardiology Source Type: news
Paclitaxel Balloons on Par With Repeat Stenting for In-Stent CTO Paclitaxel Balloons on Par With Repeat Stenting for In-Stent CTO
The incidence of long-term adverse events, however, was high with balloon angioplasty and repeat stenting, highlighting the difficulty of treating this complex patient subset.First Look (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 8, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Medtronic Receives FDA Approval for Latest Generation Drug-Eluting Coronary Stent System
Design changes include increased catheter flexibility, an innovative dual-layer balloon technology and a lower crossing profile, leading to a 16% improvement in deliverability vs. the previous generation Resolute Onyx DES. Onyx Frontier offers a broad size matrix to treat more patients and is the only 2.0 mm DES available in the United States (similar to Resolute Onyx). Further, Onyx Frontier continues to provide 4.50-5.00 mm sizes that can be expanded to 6.00 mm - specifically designed to support extra-large vessels. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 13, 2022 Category: Cardiology Source Type: news
Enrolment initiated in World's First RCT with Sirolimus Coated Balloon for the treatment of Below-the-Knee (BTK) Peripheral Artery Disease
SINGAPORE, Aug. 27, 2020 -- (Healthcare Sales & Marketing Network) -- Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the FUTURE BTK trial (Randomized Controlled Trial of Fi... Devices, Interventional Concept Medical, critical limb ischemia, angioplasty, MagicTouch PTA, sirolimus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 27, 2020 Category: Pharmaceuticals Source Type: news
What Are the Main Acyanotic Congenital Heart Diseases?
Discussion
Congenital heart diseases (CHD) are malformations of the heart and great vessels. It occurs in about 5-8/1000 live births. Cyanotic congenital heart disease is often noted perinatally because of cyanosis, respiratory distress and/or poor feeding or other distress type problems. A review can be found here.
Acyanotic congenital heart disease (ACHD) can present at birth but often is seen in older children or adults unless the lesions are severe, especially obstructive lesions. Severe lesions may also cause cyanosis and distress type problems in patients also.
Shunting lesions cause problems by diverting blood flo...
Source: PediatricEducation.org - August 17, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
COVID-19 Business Updates Provide Some Clarity
The unknowns still outnumber the knowns, but recent business updates provide some clarity around how the medical device industry is fairing during the COVID-19 pandemic. First and foremost, it is clear that companies are hurting in the areas of elective procedures, which are being deferred. But there may be some silver linings hidden amongst the bad news.
Needham & Co. medtech analyst Mike Matson estimates that medical device sales across the industry will continue to drop by an average of 40% to 50% until the economy begins to reopen and hospitals start to resume elective procedures.
Matson's e...
Source: MDDI - April 10, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: COVID-19 Business Source Type: news
FDA offers guidance on angioplasty and specialty catheters
The U.S. Food and Drug Administration (FDA) has issued a draft guidance for...Read more on AuntMinnie.comRelated Reading:
FDA offers guidance on coated devices
Cinematic rendering offers clinical utility in MSK CT
Coronary CTA beats stress test for changing lifestyles
Medtronic launches new endoscopic catheter
r4 Vascular gets FDA clearance for PTA balloon (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 10, 2020 Category: Radiology Source Type: news
20 Private Medtech Companies to Watch in 2020
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us.
So without further ado, here are the 20 companies that made the cut:
4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - December 24, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
20 Private Companies to Watch in 2020
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us.
So without further ado, here are the 20 companies that made the cut:
4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - December 24, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
5 More Private Medtech Companies to Keep Tabs On
MedTech analysts continue to keep a watchful eye on the private sector. Needham & Co.'s Mike Matson recently called attention to five private medical device companies he finds interesting, adding to three previous lists the analyst published earlier this year.
Matson was not the only medtech analyst keeping tabs on up and coming private companies in 2019. In January, Canaccord Genuity's Jason Mills highlighted 16 potentially disruptive medtech companies in the private sector.
Here are the five companies Matson most recently highlighted.
7D Surgical...
Source: MDDI - December 16, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Medtronic FDA Approval Marks a Turnaround in the Paclitaxel Story
Paclitaxel-coated balloons and paclitaxel-eluting stents caused quite the stir for manufacturers and physicians this year, but an FDA approval this week marks a major step forward for this category of devices.
The agency approved Medtronic's IN.PACT AV drug-coated balloon for the treatment of failing arteriovenous access in patients with end-stage renal disease (ESRD) undergoing dialysis.
AV fistulae are created and used to enable hemodialysis for patients with ESRD. Over time, vessel restenosis limits the ability to use AV fistulae effectively. In order to restore function, patients often undergo one to three ...
Source: MDDI - November 22, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news
Big Study Finds Many Heart Procedures Won ’t Cut Risk of Having Heart Attack
This study clearly goes against what has been the common wisdom for the last 30, 40 years” and may lead to less testing and invasive treatment for such patients in the future, said Dr. Glenn Levine, a Baylor College of Medicine cardiologist with no role in the research. Some doctors still may quibble with the study, but it was very well done “and I think the results are extremely believable,” he said.
About 17 million Americans have clogged arteries that crimp the heart’s blood supply, which can cause periodic chest pain. Cheap and generic aspirin, cholesterol-lowering drugs and blood pressure medic...
Source: TIME: Health - November 16, 2019 Category: Consumer Health News Authors: ARILYNN MARCHIONE / AP Tags: Uncategorized onetime Research Source Type: news
Boston Scientific Touts Positive Data on Two Paclitaxel Devices
Boston Scientific announced positive data Tuesday for two paclitaxel devices during separate late-breaking clinical trial presentations at the annual Vascular InterVentional Advances (VIVA) meeting in Las Vegas. Paclitaxel-coated balloons and paclitaxel-eluting stents caused quite the stir for the drug-coated balloon manufacturers and physicians this year, but presentations like these could go a long way toward helping the market rebound.
To recap, paclitaxel balloons and stents received some bad press in late December 2018 after a meta-analysis showed...
Source: MDDI - November 5, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news
